medicated paraffin oil
ApprovedSmall molecule
medicated paraffin oil is one of 19 small molecule programs targeting Poisoning. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
24 competitors in Poisoning
#DrugCompanyPhaseTrials
1Zofran
NovartisApproved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Nimotop
AAzurity Pharmaceuticals
Phase 3
Epsom Salt
FFresenius Kabi Oncology Ltd.
Phase 3
Osmitrol
BB. Braun Medical Inc.
Phase 3
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Esmeron
FFresenius Kabi Oncology Ltd.
Phase 3
Sodium Hypochlorite
AAya Sabry Mohamed Mohamed
Approved
Atropine Sulfate
CCloudbreak Therapeutics, LLC
Phase 3
Atropen
FFresenius Kabi Oncology Ltd.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Poisoning1 trial
Effectiveness of N-acetyl Cysteine, Acetyl L- Carnitine and Medicated Paraffin Oil in Aluminium Phosphide Poisoning
Unknown status·—·Phase 4·NCT04509258·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for medicated paraffin oil. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- CCairo University